ClinicalTrials.gg
CompletedNCT02908100Updated May 8, 2024Results posted

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

A Phase 2 interventional study of GDC-0853 and Placebo in Systemic Lupus Erythematosus, sponsored by Genentech, Inc.. Completed at 70 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.

Enrollment
4th of 14
260 · median 65
Started
2017
the only one that year
Phase 2
4 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 7th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfillment of SLE classification criteria according to either American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC) criteria at any time prior to or at screening
  • At least one serologic marker of SLE at screening as follows: positive antinuclear antibody (ANA) test by immunofluorescent assay with titer >/= 1:80; or positive anti-double-stranded DNA (anti-dsDNA) antibodies; or positive anti-Smith antibody
  • At both screening and Day 1, moderate to severe active SLE, defined as meeting all of the following unless indicated otherwise: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥ 8 (at screening only) with clinical SLEDAI-2K score >/= 4.0 (at both screening and Day 1), Physician's Global Assessment >/= 1.0 (out of 3), and currently receiving at least one standard oral treatment for SLE
  • If on oral (OCS), the dose must be \</= 40 mg/day prednisone (or equivalent)
  • Stable doses of anti-malarial or therapies
  • Participants must be willing to avoid pregnancy

Exclusion criteria

Exclusion Criteria:

  • Proteinuria > 3.5 g/24 h or equivalent using urine protein-to-creatinine ratio (uPCR) in a first morning void urine sample
  • Active proliferative lupus nephritis (as assessed by the investigator) or histological evidence of active Class III or Class IV lupus nephritis on renal performed in the 6 months prior to screening (or during the screening period)
  • History of having required hemodialysis or high dose (>100 mg/d) prednisone or equivalent) for the management of lupus renal disease within 90 days of Day 1
  • Neuropsychiatric or central nervous system lupus manifestations
  • Serum creatinine > 2.5 mg/dL, or estimated glomerular-filtration rate \< 30 milliliter per minute (mL/min) or on chronic renal replacement therapy
  • History of receiving a solid organ transplant
  • Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB)
  • Significant and uncontrolled medical disease within the 12 weeks prior to screening in any organ system (e.g., cardiac, neurologic, pulmonary, renal, hepatic, endocrine, metabolic, gastrointestinal, or psychiatric) not related to SLE, which, in the investigator's or Sponsor's opinion, would preclude study participation
  • History of cancer, including hematological and solid tumors, within 10 years of screening
  • Need for systemic anticoagulation with warfarin, other oral or injectable anticoagulants, or anti- agents
  • Evidence of chronic and/or active or C
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.

    Drug: Placebo

  • Experimental
    GDC-0853 (150mg) QD

    Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.

    Drug: GDC-0853

  • Experimental
    GDC-0853 (200mg) BID

    Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.

    Drug: GDC-0853

Interventions

  • Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.

    Also known as: RO7010939

  • DrugPlacebo

    Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.

06

What researchers measure

Primary outcomes

  1. Systemic Lupus Erythematosus Responder Index (SRI)-4 Response at Week 48

    The Systemic Lupus Erythematosus Responder Index (SRI)-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity.

    Time frame: Week 48

Secondary outcomes

  1. SRI-4 Response at Week 48 With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to Less Than (<)10 Milligrams Per Day (mg/Day) and Less Than or Equal to (</=) Day 1 Dose During Week 36 Through Week 48

    The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. OCS tapering requires a sustained reduction of OCS from Week 36 through Week 48 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\].

    Time frame: Week 48

  2. SRI-4 Response at Week 24 With a Sustained Reduction of OCS Dose to < 10 mg/Day and </= Day 1 Dose During Week 12 Through Week 24

    The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. OCS tapering requires a sustained reduction of OCS from Week 12 through Week 24 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\].

    Time frame: Week 24

  3. SRI-4 Response at Week 24

    The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity.

    Time frame: Week 24

  4. SRI-4 Response at Week 48 in Patients With High vs. Low Plasmablast Signature Levels

    The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. The Plasmablast Signature (PB) is a Bruton's Tyrosine Kinase (BTK)-dependent blood RNA signature comprised of three genes (IgJ, MZB1 and TXNDC5). Q1/2/3/4 = Quartile 1/2/3/4.

    Time frame: Week 48

  5. SRI-4 Response With a Sustained Reduction of OCS Dose to ≤ 10 mg/Day and ≤ Day 1 Dose During Week 36 Through 48 in Patients With High vs. Low Plasmablast Signature Levels

    The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. The Plasmablast Signature (PB) is a Bruton's Tyrosine Kinase (BTK)-dependent blood RNA signature comprised of three genes (IgJ, MZB1 and TXNDC5). Q1/2/3/4 = Quartile 1/2/3/4.

    Time frame: Week 48

  6. SRI-6 Response at Week 24 and 48

    The Systemic Lupus Erythematosus Responder Index (SRI)-6 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥6 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity.

    Time frame: Week 24, 48

  7. BILAG-based Composite Lupus Assessment (BICLA) Response at Week 24 and 48

    The BICLA is a composite index that is defined as follows: \[1\] At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry (e.g., all A (severe disease) scores falling to B (moderate), C (mild), or D (no activity) and all B scores falling to C or D; \[2\] No new BILAG A or more than one new BILAG B scores; \[3\] No worsening of total SLEDAI-2K score from baseline; \[4\] No significant deterioration (=\<10%) in physician's global assessment and \[5\] No treatment failure (initiation of non-protocol treatment).

    Time frame: Week 24, 48

  8. Percentage of Participants With Adverse Events (AEs)

    An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to 8 weeks after the last dose of study drug (up to Week 56).

  9. Plasma Concentrations of Fenebrutinib at Specified Timepoints

    The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.

    Time frame: Baseline (Pre-dose), Week 24 (Pre-dose and Post-dose) and Week 48 (Pre-dose)

07

Results

Posted Jul 7, 2020

Participant flow

The study was conducted at 69 centers in 12 countries.

Participant flow — Overall Study
MilestonePlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Started868787
Completed636666
Not completed232121
Withdrew: Adverse event769
Withdrew: Death200
Withdrew: Lack of efficacy233
Withdrew: Lost to follow-up012
Withdrew: Non-compliance with study drug112
Withdrew: Non-compliance with contraceptive method100
Withdrew: Physician decision010
Withdrew: Pregnancy120
Withdrew: Withdrawal by subject875
Withdrew: Randomised in error100

Outcome measures

PrimarySystemic Lupus Erythematosus Responder Index (SRI)-4 Response at Week 48

The Systemic Lupus Erythematosus Responder Index (SRI)-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Systemic Lupus Erythematosus Responder Index (SRI)-4 Response at Week 48
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Systemic Lupus Erythematosus Responder Index (SRI)-4 Response at Week 4844.250.651.7
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.373 · Absolute difference: 6.4 · 95% CI -8.5 to 21.2
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.339 · Absolute difference: 7.5 · 95% CI -7.3 to 22.4
SecondarySRI-4 Response at Week 48 With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to Less Than (<)10 Milligrams Per Day (mg/Day) and Less Than or Equal to (</=) Day 1 Dose During Week 36 Through Week 48

The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. OCS tapering requires a sustained reduction of OCS from Week 36 through Week 48 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\].

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
SRI-4 Response at Week 48 With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to Less Than (<)10 Milligrams Per Day (mg/Day) and Less Than or Equal to (</=) Day 1 Dose During Week 36 Through Week 48
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
SRI-4 Response at Week 48 With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to Less Than (<)10 Milligrams Per Day (mg/Day) and Less Than or Equal to (</=) Day 1 Dose During Week 36 Through Week 4841.950.644.8
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.223 · Absolute difference: 8.7 · 95% CI -6.1 to 23.5
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.737 · Absolute difference: 3.0 · 95% CI -11.8 to 17.7
SecondarySRI-4 Response at Week 24 With a Sustained Reduction of OCS Dose to < 10 mg/Day and </= Day 1 Dose During Week 12 Through Week 24

The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. OCS tapering requires a sustained reduction of OCS from Week 12 through Week 24 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\].

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
SRI-4 Response at Week 24 With a Sustained Reduction of OCS Dose to < 10 mg/Day and </= Day 1 Dose During Week 12 Through Week 24
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
SRI-4 Response at Week 24 With a Sustained Reduction of OCS Dose to < 10 mg/Day and </= Day 1 Dose During Week 12 Through Week 2443.047.147.1
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.614 · Absolute difference: 4.1 · 95% CI -10.7 to 18.9
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.607 · Absolute difference: 4.1 · 95% CI -10.7 to 18.9
SecondarySRI-4 Response at Week 24

The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
SRI-4 Response at Week 24
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
SRI-4 Response at Week 2446.552.952.9
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.410 · Absolute difference: 6.4 · 95% CI -8.5 to 21.2
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.418 · Absolute difference: 6.4 · 95% CI -8.5 to 21.2
SecondarySRI-4 Response at Week 48 in Patients With High vs. Low Plasmablast Signature Levels

The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. The Plasmablast Signature (PB) is a Bruton's Tyrosine Kinase (BTK)-dependent blood RNA signature comprised of three genes (IgJ, MZB1 and TXNDC5). Q1/2/3/4 = Quartile 1/2/3/4.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
SRI-4 Response at Week 48 in Patients With High vs. Low Plasmablast Signature Levels
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Plasmablast Signature Level Q137.552.445.0
Plasmablast Signature Level Q254.554.263.2
Plasmablast Signature Level Q336.852.452.0
Plasmablast Signature Level Q450.042.947.8
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.378 · Absolute difference: 14.9 · 95% CI -14 to 43.7
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.732 · Absolute difference: 7.5 · 95% CI -21.7 to 36.7
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.500 · Absolute difference: -0.4 · 95% CI -29.2 to 28.4
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.234 · Absolute difference: 8.6 · 95% CI -21.4 to 38.7
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.364 · Absolute difference: 15.5 · 95% CI -14.9 to 46
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.134 · Absolute difference: 15.2 · 95% CI -14.1 to 44.4
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.830 · Absolute difference: -7.1 · 95% CI -37.6 to 23.3
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.963 · Absolute difference: -2.2 · 95% CI -32.1 to 27.8
SecondarySRI-4 Response With a Sustained Reduction of OCS Dose to ≤ 10 mg/Day and ≤ Day 1 Dose During Week 36 Through 48 in Patients With High vs. Low Plasmablast Signature Levels

The SRI-4 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity. The Plasmablast Signature (PB) is a Bruton's Tyrosine Kinase (BTK)-dependent blood RNA signature comprised of three genes (IgJ, MZB1 and TXNDC5). Q1/2/3/4 = Quartile 1/2/3/4.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
SRI-4 Response With a Sustained Reduction of OCS Dose to ≤ 10 mg/Day and ≤ Day 1 Dose During Week 36 Through 48 in Patients With High vs. Low Plasmablast Signature Levels
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Plasmablast Signature Level Q133.352.440.0
Plasmablast Signature Level Q254.554.257.9
Plasmablast Signature Level Q336.852.444.0
Plasmablast Signature Level Q445.042.939.1
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.189 · Absolute difference: 19.0 · 95% CI -9.4 to 47.5
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.909 · Absolute difference: 6.7 · 95% CI -21.9 to 35.2
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.500 · Absolute difference: -0.4 · 95% CI -29.2 to 28.4
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.234 · Absolute difference: 3.3 · 95% CI -27.1 to 33.8
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.364 · Absolute difference: 15.5 · 95% CI -14.9 to 46
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.310 · Absolute difference: 7.2 · 95% CI -22 to 36.3
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.922 · Absolute difference: -2.1 · 95% CI -32.5 to 28.2
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.701 · Absolute difference: -5.9 · 95% CI -35.4 to 23.7
SecondarySRI-6 Response at Week 24 and 48

The Systemic Lupus Erythematosus Responder Index (SRI)-6 measures reduction in SLE disease activity and is a composite measure that includes the SLE Disease Activity Index (SLEDAI-2K), British Isles Lupus Activity Group (BILAG) 2004 and Physician Global Assessment. It is defined as: 1) Reduction of ≥6 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in the Physician's Global Assessment of Disease Activity. The score range is from 0 to 100, with higher scores indicating greater disease activity.

Time frame:
Week 24, 48
Reported as:
Number · Percentage of Participants
SRI-6 Response at Week 24 and 48
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Week 2431.434.533.3
Week 4827.939.135.6
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.692 · Absolute difference: 3.1 · 95% CI -10.9 to 17.1
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.871 · Absolute difference: 1.9 · 95% CI -12 to 15.9
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.105 · Absolute difference: 11.2 · 95% CI -2.8 to 25.1
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.286 · Absolute difference: 7.7 · 95% CI -6.1 to 21.6
SecondaryBILAG-based Composite Lupus Assessment (BICLA) Response at Week 24 and 48

The BICLA is a composite index that is defined as follows: \[1\] At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry (e.g., all A (severe disease) scores falling to B (moderate), C (mild), or D (no activity) and all B scores falling to C or D; \[2\] No new BILAG A or more than one new BILAG B scores; \[3\] No worsening of total SLEDAI-2K score from baseline; \[4\] No significant deterioration (=\<10%) in physician's global assessment and \[5\] No treatment failure (initiation of non-protocol treatment).

Time frame:
Week 24, 48
Reported as:
Number · Percentage of Participants
BILAG-based Composite Lupus Assessment (BICLA) Response at Week 24 and 48
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Week 2447.545.944.6
Week 4841.252.942.2
Statistical analysis
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.936 · Absolute difference: -1.6 · 95% CI -16.8 to 13.6
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.683 · Absolute difference: -2.9 · 95% CI -18.2 to 12.4
  • Placebo vs GDC-0853 (150mg) QD · Cochran-Mantel-Haenszel · p = 0.086 · Absolute difference: 11.7 · 95% CI -3.4 to 26.8
  • Placebo vs GDC-0853 (200mg) BID · Cochran-Mantel-Haenszel · p = 0.879 · Absolute difference: 0.9 · 95% CI -14.2 to 16.1
SecondaryPercentage of Participants With Adverse Events (AEs)

An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to 8 weeks after the last dose of study drug (up to Week 56).
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Percentage of Participants With Adverse Events (AEs)76.288.578.4
SecondaryPlasma Concentrations of Fenebrutinib at Specified Timepoints

The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.

Time frame:
Baseline (Pre-dose), Week 24 (Pre-dose and Post-dose) and Week 48 (Pre-dose)
Reported as:
Mean · ng/mL
Plasma Concentrations of Fenebrutinib at Specified Timepoints
ng/mLGDC-0853 (150mg) QDGDC-0853 (200mg) BID
Week 0 (Pre-dose)NA ± NANA ± NA
Week 24 (Pre-dose)41.9 ± 62.4180 ± 121
Week 24 (2hr Post-dose)331 ± 226612 ± 353
Week 24 (4-6hr Post-dose)215 ± 131414 ± 187
Week 24 (8-10hr Post-dose)120 ± 111233 ± 145
Week 48 (Pre-dose)25.5 ± 28.1137 ± 133

Adverse events

Collected over Baseline up to 8 weeks after the last dose of study drug (up to Week 56).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/84 (2.4%)9/84 (10.7%)42/84 (50%)
GDC-0853 (150mg) QD1/87 (1.1%)4/87 (4.6%)54/87 (62.1%)
GDC-0853 (200mg) BID0/88 (0%)12/88 (13.6%)51/88 (58%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders2/841/872/88
CONGESTIVE CARDIOMYOPATHYCardiac disorders1/840/870/88
MULTIPLE ORGAN DYSFUNCTION SYNDROMEGeneral disorders1/840/870/88
EPSTEIN-BARR VIRUS INFECTIONInfections and infestations1/840/870/88
GASTROENTERITIS BACTERIALInfections and infestations1/840/870/88
INFECTED SKIN ULCERInfections and infestations1/840/870/88
PNEUMONIAInfections and infestations1/840/870/88
PYELONEPHRITISInfections and infestations1/840/871/88
SEPTIC SHOCKInfections and infestations1/840/870/88
URINARY TRACT INFECTIONInfections and infestations1/840/871/88
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BID
URINARY TRACT INFECTIONInfections and infestations9/8417/8711/88
LYMPHOPENIABlood and lymphatic system disorders6/842/8710/88
HEADACHENervous system disorders9/843/873/88
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations5/849/873/88
NASOPHARYNGITISInfections and infestations5/848/876/88
BACK PAINMusculoskeletal and connective tissue disorders2/848/874/88
NAUSEAGastrointestinal disorders7/844/877/88
BRONCHITISInfections and infestations6/846/877/88
DIARRHOEAGastrointestinal disorders6/845/875/88
NEUTROPENIABlood and lymphatic system disorders4/845/876/88

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BIDTotal
Mean40.2 ± 11.543.3 ± 12.440.4 ± 10.641.3 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BIDTotal
Female858284251
Male1539
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BIDTotal
Hispanic or Latino546161176
Not Hispanic or Latino32252683
Not Stated0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGDC-0853 (150mg) QDGDC-0853 (200mg) BIDTotal
American Indian or Alaska native1181736
Asian71210
Black or African American11151339
Multiple1135
White566252170
08

Study locations

70 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Valerius Medical Group & Research Ctr of Greater Long Beach
    Los Alamitos, California 90720, United States
  • RASF-Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Bay Area Arthritis and Osteoporosis
    Brandon, Florida 33511, United States
  • Omega Research Consultants
    Orlando, Florida 32810, United States
  • Clinical Research of West Florida
    Tampa, Florida 33603, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Via Christi Research, a division of Via Christi Hospitals Wichita, Inc.
    Wichita, Kansas 67208, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70809, United States
  • The Arthritis & Diabetes Clinic, Inc.; Research
    Monroe, Louisiana 71203, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Saint Lawrence Health System
    Canton, New York 13617, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Shanahan Rheumatology & Immunology, PLLC
    Raleigh, North Carolina 27617, United States
  • Ohio State University Clinical Trials Management Office
    Columbus, Ohio 43210, United States
  • Tekton Research Inc
    Austin, Texas 78745, United States
  • Accurate Clinical Research
    Houston, Texas 77058-3675, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Arthritis Clinic Of Central Texas
    San Marcos, Texas 78666, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • APRILLUS
    Buenos Aires, C1194AAO, Argentina
  • Hospital Italiano de La Plata
    La Plata, 1900, Argentina
  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
    San Juan, 5400, Argentina
  • Centro Medico Privado de Reumatologia; Reumathology
    San Miguel, T4000AXL, Argentina
  • CEDOES - Diagnóstico e Pesquisa
    Vitoria, ES 29055-450, Brazil
  • CIP - Centro Internacional de Pesquisa X; Pesquisa Clinica
    Goiânia, GO 74110-120, Brazil
  • Hospital das Clinicas - UFMG
    Belo Horizonte, MG 31270-901, Brazil
  • CMiP - Centro Mineiro de Pesquisa*X*
    Juiz de Fora, MG 36010-570, Brazil
  • Edumed - Educação e Saúde SA
    Curitiba, PR 80440-080, Brazil
  • Hospital Moinhos de Vento
    Porto Alegre, RS 90035-001, Brazil
  • Centro de Pesquisas em Diabetes - CPD
    Porto Alegre, RS 90035-170, Brazil
  • Clinica de Neoplasias Litoral
    Itajai, SC 88301-220, Brazil
  • Faculdade de Medicina do ABC - FMABC
    Santo Andre, SP 09060-650, Brazil
  • Hospital Estadual Mario Covas
    Santo Andre, SP 09190-610, Brazil
  • Hospital Abreu Sodré - AACD
    Sao Paulo, SP 04023-000, Brazil
  • MHAT Plovdiv
    Plovdiv, 4003, Bulgaria
  • Medical Center "Teodora", EOOD
    Ruse, 7000, Bulgaria
  • Medical Center Excelsior OOD
    Sofia, 1000, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • MC "Synexus - Sofia", EOOD
    Sofia, 1784, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • CTR Estudios SPA
    Providencia, 7500571, Chile
  • Dermacross
    Santiago, 66901, Chile
  • Centro de Estudios Reumatológicos
    Santiago, 7501126, Chile
  • SOMEAL
    Santiago, 7510186, Chile
  • Biomedica
    Santiago, Chile
  • CEQUIN - Fundación Cardiomet Eje Cafetero
    Armenia, 00000, Colombia
  • Centro Integral de Reumatologia del Caribe SAS CIRCARIBE SAS
    Barranquilla, 00000, Colombia
  • Centro de Reumatologia y Ortopedia
    Barranquilla, 80020, Colombia
  • Medicity S.A.S.
    Bucaramanga, 680003, Colombia
  • Servimed S.A.S.
    Bucaramanga, 680003, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, 050034, Colombia
  • Charite Research Organisation GmbH; Phase - I Unit of Hematology and Oncology
    Berlin, 12200, Germany
  • Konkuk University Medical Center
    Seoul, 05030, Korea, Republic of
  • The Catholic University of Korea St.Mary's Hospital
    Seoul, 150-713, Korea, Republic of
  • Centro de Investigacion Alberto Bazzoni S.A. de C.V.
    Torreon, Coahuila 27000, Mexico
  • Unidad de Atencion Medica e Investigacion en Salud S.C.
    Mérida, Yucatan 97000, Mexico
  • Consultorio Particular del Dr. Miguel Cortes Hernandez
    Cuernavaca, 62290, Mexico
  • Hospital Angeles Lindavista
    Mexico, 07760, Mexico
  • Hospital Universitario de Saltillo
    Saltillo, 25000, Mexico
  • Hospital Central Dr Ignacio Morones Prieto
    San Luis Potosi, 78240, Mexico
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, LA Coruña 15006, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Clinico Universitario de Valladolid; Servicio de Reumatologia
    Valladolid, 47005, Spain
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, 00833, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Chang Gung Memorial Hospital - Linkou
    Taoyuan, 333, Taiwan
  • University College London Hospital
    London, NW1 - 2PG, United Kingdom
  • Guy's Hospital; Louise Coote Lupus Unit
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, McGregor A, Toth B, Rae J, Hwang O, Desai R, Lokku A, Ramamoorthi N, Hackney JA, Miranda P, de Souza VA, Jaller-Raad JJ, Maura Fernandes A, Garcia Salinas R, Chinn LW, Townsend MJ, Morimoto AM, Tuckwell K. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021 Oct;73(10):1835-1846. doi: 10.1002/art.41811. Epub 2021 Aug 24. PubMed 34042314 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in May 2019, 28 months.

Results were first posted in Jul 2020, 1 year 1 month after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 28 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Sep 20, 2016
StartActual
Jan 19, 2017
Primary completionActual
May 28, 2019
CompletionActual
Jul 16, 2019
Results first posted
Jul 7, 2020
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02908100
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Jan 19, 2017
Primary completion
May 28, 2019
Completion
Jul 16, 2019
Results posted
Jul 7, 2020
Last update
May 8, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion